Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD0292 · 2 trials · 1 indication
To evaluate the effect of IV AZD0292 compared to placebo on the rate of moderate-to severe pulmonary exacerbations in participants with NCFBE and chronic colonization with PsA
| Arm | Type | Description |
|---|---|---|
| AZD0292 | EXPERIMENTAL | AZD0292 administered starting on Day 1, subsequent administrations per schedule of assessments. |
| Placebo | PLACEBO_COMPARATOR | Placebo administered starting on Day 1, subsequent administrations per schedule of assessments. |
| High-dose | EXPERIMENTAL | High-Dose AZD0292 administered starting on Day 1, subsequent administrations per schedule of assessments. |
| Low-dose | EXPERIMENTAL | Low-dose AZD0292 administered starting on Day 1, subsequent administrations per schedule of assessments. |
| Name | Type | Description |
|---|---|---|
| AZD0292 | DRUG | AZD0292 administered starting on Day 1 via IV infusion, subsequent administrations per schedule of assessments. |
| Placebo | OTHER | Placebo administered starting on Day 1 via IV infusion, subsequent administrations per schedule of assessments. |
Inclusion Criteria: * Participant must be ≥ 18 years of age at the time of signing the informed consent/assent. * Weight ≥ 35 kg. * Bronchiectasis diagnosed by a physician and confirmed by CT demonstrating abnormal bronchial dilation in ≥ 1 lobe. Note: A historical CT scan within the past 5 years i...
AZD0292 is being developed for bronchiectasis with chronic Pseudomonas aeruginosa colonization, a respiratory condition in which the airways are damaged and persistently infected by that bacterium. It is an investigational monoclonal antibody and has not been approved for any use. Both of its clinical trials enroll participants with this specific indication.
AZD0292 is developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca sponsors both of the drug's Phase 2 studies, one in China and one running across the United States, Europe, Asia, Latin America, and other regions.
AZD0292 is in Phase 2 clinical development. It is investigational and has not been approved by the FDA or any other regulator. Two Phase 2 trials are currently recruiting, with no completed trials to date, and the two studies together plan to enroll 519 participants.
AZD0292 is being studied in two recruiting Phase 2 trials. NCT07774403 is a study in Chinese participants with bronchiectasis and chronic Pseudomonas aeruginosa colonization, enrolling 84 people. NCT07088926 evaluates efficacy, safety, and pharmacokinetics of intravenous AZD0292 in participants 12 years and older, enrolling 435 people across 25 countries.
Both AZD0292 trials are randomized, double-blind, and placebo-controlled Phase 2 studies in bronchiectasis with chronic Pseudomonas aeruginosa colonization. NCT07088926 enrolls participants aged 12 and older across 25 countries, while NCT07774403 is limited to China. Neither trial selects participants by biomarker, and healthy volunteers are not enrolled.